scholarly journals A FRAMEWORK FOR DEVELOPING A MODEL STRUCTURE OF BUDGET IMPACT ANALYSIS FOR NEW HEALTH CARE INTERVENTIONS IN JORDAN

2021 ◽  
Vol 11 (1) ◽  
pp. 126-134
Author(s):  
Eman Mohammad Massad ◽  
Amir Bakir
Keyword(s):  
Health Care ◽  
Impact Analysis ◽  
Budget Impact ◽  
Budget Impact Analysis ◽  
Model Structure ◽  
Health Care Interventions

Budget-Impact Analysis of Health Care Interventions

2017 ◽  
Author(s):  
Josephine Mauskopf ◽  
Stephanie R. Earnshaw ◽  
Anita Brogan ◽  
Sorrel Wolowacz ◽  
Thor-Henrik Brodtkorb
Keyword(s):  
Health Care ◽  
Impact Analysis ◽  
Budget Impact ◽  
Budget Impact Analysis ◽  
Health Care Interventions

scholarly journals Budget impact analysis of a breast rapid diagnostic unit

2017 ◽  
Vol 24 (3) ◽  
pp. 214 ◽  
Author(s):  
M. Elmi ◽  
H. Hussain ◽  
S. Nofech-Mozes ◽  
B. Curpen ◽  
A. Leahey ◽  
...  
Keyword(s):  
Health Care ◽  
Impact Analysis ◽  
Budget Impact ◽  
Tertiary Care ◽  
Resource Planning ◽  
Budget Impact Analysis ◽  
Sensitivity Analyses ◽  
Definitive Treatment ◽  
Base Case ◽  
Diagnostic Unit

Background The Odette Cancer Centre’s recent implementation of a rapid diagnostic unit (rdu) for breast lesions has significantly decreased wait times to diagnosis. However, the economic impact of the unit remains unknown. This project defined the development and implementation costs and the operational costs of a breast rdu in a tertiary care facility.Methods From an institutional perspective, a budget impact analysis identified the direct costs associated with the breast rdu. A base-case model was also used to calculate the cost per patient to achieve a diagnosis. Sensitivity analyses computed costs based on variations in key components. Costs are adjusted to 2015 valuations using health care–specific consumer price indices and are reported in Canadian dollars.Results Initiation cost for the rdu was $366,243. The annual operational cost for support staff was $111,803. The average per-patient clinical cost for achieving a diagnosis was $770. Sensitivity analyses revealed that, if running at maximal institutional capacity, the total annual clinical cost for achieving a diagnosis could range between $136,080 and $702,675.Conclusions Establishment and maintenance of a breast rdu requires significant investment to achieve reductions in time to diagnosis. Expenditures ought to be interpreted in the context of institutional patient volumes and trade-offs in patient-centred outcomes, including lessened patient anxiety and possibly shorter times to definitive treatment. Our study can be used as a resource-planning tool for future rdus in health care systems wishing to improve diagnostic efficiency.

Concept of Combining Cost-Effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making

2017 ◽  
Vol 13 ◽  
pp. 61-66 ◽  
Author(s):  
Roza Ismailovna Yagudina ◽  
Andrey Urievich Kulikov ◽  
Vjacheslav Gennadievich Serpik ◽  
Dzhumber Tengizovich Ugrekhelidze
Keyword(s):  
Health Care ◽  
Decision Making ◽  
Cost Effectiveness ◽  
Impact Analysis ◽  
Budget Impact ◽  
Cost Effectiveness Analysis ◽  
Budget Impact Analysis ◽  
Health Care Decision ◽  
Effectiveness Analysis ◽  
Care Decision

scholarly journals Budget impact analysis of use of aliskiren in hypertension on the Italian Health Care System

2009 ◽  
Vol 10 (1) ◽  
pp. 5-18
Author(s):  
Orietta Zaniolo ◽  
Lorenzo Pradelli
Keyword(s):  
Blood Pressure ◽  
Health Care ◽  
Blood Pressure Control ◽  
Impact Analysis ◽  
Budget Impact ◽  
Pressure Control ◽  
Budget Impact Analysis ◽  
Cost Driver ◽  
Total Direct Cost ◽  
Pharmaceutical Expenditures

Cardiovascular (CV) disease management and prevention has been the leading cost driver in health care expenditures of industrialized Countries for many years, and this trend is not expected to change in the next future. Although drugs used for the treatment of arterial hypertension and heart failure account for three fourths of the total Italian pharmaceutical expenditures in this disease area, population studies indicate that only about half of all hypertensive patients are treated for this condition, and that, among treated individuals, only a minority achieves a satisfactory and stable blood pressure control. A complementary observation is that drug expenditures, as high as they seem to be, actually account for only about a fourth of the total direct cost of CV illness, as they are exceeded by costs of hospitalizations required for the acute management of the clinical events that should be, at least partially, prevented by the same cardiovascular drugs. An often pointed out corollary to these findings is that an increase in the rate of controlled hypertension in the population, although surely linked to a further increase in pharmaceutical expenditures, carries the potential to reduce overall health care costs for the management of CV patients. As far as drug treatment is concerned, there seem to be three applicable strategies capable of increasing blood pressure control rates, i.e. interventions directed toward the increase of the treated population, interventions aimed at improving compliance, and the introduction of innovative drugs to cover unmet needs. Aliskiren is the first agent of the new direct renin inhibitors drug class, and has been recently approved in Italy under strict reimbursement restrictions. In this paper, the Authors present a budget impact analysis in the perspective of the National Health Service, conducted by estimating eligible populations according to reimbursement limitations, calculating differential costs by patient subgroups and possible strategies (addition to vs substitution of ACE-Is or ARBs), and finally by applying expected market shares to the identified population. The low forecast market penetration (0.2% and 0.6% of eligible patients, in the first and second year, respectively) drives the results: the treatment of 3,274-9,821 patients induces a yearly increase of 1.5 to 4.5 million € with aliskiren added to ACE-Is or ARBs, and of 917,000 to 2,751,000 € in the substitution scenario.

Sign in / Sign up

Export Citation Format

Share Document